Terrestrial Bio Wins Biotech Breakthrough Award for Therapeutics Platform of the Year 

Company’s Tacterra™ microarray patch and applicator platform is designed for precise, self-administered therapeutic delivery without medical sharps or refrigeration

BOSTON, November 9, 2026 — Terrestrial Bio today announced that its Tacterra™ microarray patch (MAP) and applicator platform has been named Therapeutics Platform of the Year in the Biotech Breakthrough Awards. 

“At Terrestrial Bio, we are working toward a future where people can access transformative medicines that are easier to use and available wherever they are, without compromising efficacy,” said Rachel Sha, CEO of Terrestrial Bio. “We are honored to receive a Biotech Breakthrough for Tacterra, a best-in-class platform that moves therapeutic delivery from needles to an easy-to-apply skin patch.”

Terrestrial's proprietary Tacterra™ platform consists of a patch resembling an adhesive bandage, which is applied with a preloaded applicator and removed after a few minutes. Once applied, each patch delivers bioactive tips into the skin, which rapidly release their therapeutic payload as they dissolve into the body. The first commercial use of the Tacterra platform will be delivering GLP-1 therapies, providing people with an easier way to manage their weight and optimize health. Designed for self-administration, the temperature-stable Tacterra™ platform will enable precise, controlled delivery of a wide range of therapeutics without medical sharps or refrigeration.

Terrestrial is receiving the Biotech Breakthrough Award for Therapeutics Platform of the Year during a time of significant growth for the company. In 2026, the company announced a $50 million Series C financing and the start of a Phase 1 clinical trial evaluating VX-201, its investigational Tacterra™ microarray patch for GLP-1 delivery. Recently, Terrestrial opened its new manufacturing facility and headquarters in Boston, designed to support production of Terrestrial’s Tacterra microarray patches for clinical trials and future commercial production.

To read about all of the winners of the Biotech Breakthrough Awards, visit https://biotechbreakthroughawards.com/2026-winners/

About Terrestrial Bio, Inc.

Terrestrial is transforming the delivery of next-generation therapies, starting with GLP-1.

Terrestrial has generated strong clinical and in vivo proof of concept across multiple molecules. For more information, visit www.terrestrialbio.com.